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~ problem. This study determined the effect of 
leucogenenol. an untried immunostimulant. in conjunction 
with known effective chemotherapy on mouse leukemia L1210. 
Procedure. L1210 infected animals in various treat­
ment groups were monitored for changes in several parameters 
of the disease. Among these parameters were differential 
smears, hematocrits. total nucleated cell counts. spleen and 
liver weights to total body weight ratios and survival times. 
Findings. Although some of the parameters of the 
leukemia were decreased after leucogenenol therapy. a minimal 
detrimental effect was observed in the survival times of the 
animals. The humoral antibody levels were elevated after 
leucogenenol and chemotherapeutic treatment, but these were 
obviously not effective in controlling the number of prolifer­
ating L1210 leukemic cells. 
Conclusion. It was concluded that leucogenenol was 
able to increase the humoral antibody response but not the 
number of sensitized lymphocytes such that the residual 
leukemic cells could be destroyed immunologically. Hence, 
even in combination with chemotherapy, leucogenenol's action 
could not turn the race between the residual leukemic cells 
and sensitized lymphocytes in favor of the host. 
Recommendations. The recent demonstration of immuno­
logical enhancement of a tumor by humoral antibodies makes it 
important to determine if leucogenenol's action is specific 
for the B lymphoid cells or does it affect both the Band T 
lymphoid cells? A method for determining the molecular action 
of leucogenenol might lead to a greater understanding of the 
control of hematopoiesis and leukemias. 
THE EFFECT OF LEUCOGENENOL AND CHEMOTHERAPY
 
ON LEUKEMIA L1210
 
A Thesis
 
Presented to
 
The School of Graduate Studies
 
Drake University
 
In Partial Fulfillment
 
of the Requirements for the Degree
 
Master of Arts
 
by 
Mark Alan Barnhill
 
August 1973
 
") ,/. 
THE EFFECT OF LEUCOGENENOL AND CHEMOTHERAPY
 
ON LEUKEMIA L1210
 
by 
Mark Alan Barnhill 
Approved by Committee. 
I ' 
Dean of the School ot Graduate Studies 
• • • • • • • 
TABLE OF CONTENTS
 
Page 
INTRODUCTION AND REVIEW OF THE LITERATURE • 1• 
METHODS AND l'fLATERIALS • 
• 15• 
RESULTS • • • • 19 
DISCUSSION • • • 45 
SUM.MARY • 50 
LITERATURE CITED • • • 52o 
LIST OF TABLES 
TABLE PAGE 
1.	 Average differential counts. 20 
2. Average hematocrit values. 25 
3· Average peripheral nucleated cell counts x 103 
cells/cu mm.	 29 
4.	 Average survival times in days. 33 
5·	 Average ratio of the spleen and liver weight 
to the total body weight. 36 
6.	 Average hemagglutination and complement­
fixation titers to SRBC at day 7 and day 14 
(expressed as Log2 ). 40 
LIST OF FIGURES 
FIGURE	 PAGE 
1.	 Average percent lymphoid cells from peripheral 
smears. 22 
2.	 Average hematocrit values. 27 
3.	 Average peripheral total nucleated cell counts 
x 10) cells/cu mm. 31 
4.	 Average survival time in days. 35 
5.	 Average weight ratio of the liver and spleen 
compared to the total body weight. 38 
6.	 Average SRBC hemagglutination titers expressed 
as Log2 • 42 
7.	 Average SRBC hemolysin titers expressed as Log2 • 44 
INTRODUCTION AND REVIEW OF THE LITERATURE 
Remission of a tumor involves the elimination or the 
control of growth of a tumor cell population and is sUbject 
to a balance of factors pertaining to the drug, tumor and 
the host. Three important variables which have an influence 
on the attainment of complete remission are the extent of 
drug action on the tumor cells, the drug toxicity for the 
host tissue, and the immunocompetence of the host. Recent 
research has dealt with a combination of chemotherapy and 
immunotherapy in which maximum destruction of the tumor 
cells is followed by either specific or non-specific immuno­
logical stimulation to kill the remainder of the tumor cells 
present and/or to prevent the growth of new tumor cells. In 
this study combined chemotherapy of Leukemia L1210 with 
known effective drugs will be accompanied by immunotherapy 
with an untried immunostimulant, leucogenenol. 
Leukemia L1210 
Leukemia L1210, a tumor originally found in an animal 
treated with methylcholanthracene, was first reported by Law 
et ale (1949). The initial tumor arose in a female DBA mouse, 
subline 212, at 8 months of age following skin paintings with 
0.2% methylcholanthracene in ethyl ether. The tumor still 
only grows in DBA mice and in F1 hybrids and backcrosses 
derived from it (Mihich and Kitano, 1971). The disease was 
characterized by a great enlargement of the axillary, inguinal 
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and cervical lymph nodes and moderate enlargement of the 
spleen and liver. Law also reported enlargement of the 
internal lymph nodes and the thymus as well as extensive 
infil tration of the kidneys with leukemic cells. Following 
the inocula~ion of leukemic cells. there is a rapid local 
growth with infilt~tion of the cells into the liver. spleen. 
subcutaneous lymph nodes and internal lymph nodes. Wi thin 
48 hours. immature lymphoid cells are found in the peripheral 
blood. This proliferation in the blood is followed by mas­
sive inf'il tration of the tissue resul ting in the death of the 
animal approximately 8 days after challenge. The rapid death 
was attributed to infarctions occurring in the vital tissues 
and organs. This leukemia has since this time been carried in 
DBA mice by intraperitoneal or intramuscular passage of viable 
cells suspended in a balanced salt solution. Although lX105 
viable cells are usually injected to transplant the tumor. 
Schabel et ale (1966) showed that a single viable L1210 cell 
isolated with a micromanipUlator and transplanted into a 
BDF mouse gives rise to a population of cells that quadruples1 
daily reSUlting in about 1 billion widely disseminated cells 
and death of the mouse in 15 to 18 days. 
Skipper et ale (1967) showed that the average doubling 
time and the average generation time of L1210 leukemic cell 
populations are approximately equal. In contrast, Yankee 
et ala (1967) determined from radio-autograph studies that 
the generation time was 11.7 hours with a dOUbling time of 
3 
14·5 hours. This apparent discrepancy was explained by the 
extensive migration of the cells from the peritoneum during 
the course of the study. The period of DNA synthesis during 
the cell cycle was 8.9 hours and occupied 75% of the entire 
cell cycle. An elongation of the cell cycle as the tumor 
enlarges has been shown to be consistent with the crowding 
effect of a rapidly growing tumor in which the potential to 
proliferate is maintained b~t delayed (Dombernowsky and 
Hartmann, 1972). 
Gresser et ale (1970) demonstrated that various mouse 
interferon preparations inhibited the multiplication of 
L1210 cells in cell suspension, and the degree of inhibition 
was found to be directly related to the anti-viral titers of 
the preparation. This finding has led to a search for a 
viral etiology for Leukemia L1210, but at this time although 
A-type particles have been seen and isolated from L1210 
infected animals, viruses have not been conclusively demon­
strated as a causitive agent for the leukemia (Brandes et al., 
1966 and Kuff et al., 1972). 
Glynn et ale (1963) established that CDF1 mice are 
competent to react immunologically against L1210 leukemic 
cells. However, this immunological response varies over the 
course of the tumor growth. When CDF1 mice were immunized 
to sheep erythrocytes (SRBC) during the early stages of the 
L1210 growth, a definite increase in the number of anti-SRBC 
plaque forming cells per spleen was observed. If immunization 
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was delayed until an advanced stage of the disease, a de­
creased immunological response was found (Bonmasser et al., 
1971). Thus, as the tumor growth progresses, the animal 
becomes progressively less immunoresponsive. 
Goldin and Humphreys (1960) demonstrated that mice 
surviVing systemic Leukemia L1210 after treatment with 
halogenated derivatives of amethopterin may be refractory 
to reinoculation of L1210 leukemic cells. Further evidence 
of an immune response to L1210 was demonstrated by Glynn, 
et al. (196). They immunized CBBA mice against L1210 by 
mUltiple inOCUlations of irradiated leukemic splenic tissue 
from DBA/2 mice of one of the parental types. These mice 
were later challenged with L1210 tumor cells and exhibited 
no signs of the leukemia. Hence, it is possible to mount a 
successful immunological response to the L1210 leukemic 
cells; however, the response would vary with the stage of the 
disease and the kind, amount and success of chemotherapy and 
immunotherapy. 
Chemother l3.PY 
There has been much experimentation to test the 
effectiveness of various types of chemotherapy against lym­
phoid leukemias. Leukemia L1210 is now routinely used by 
many as the standard against which new drugs are tested. 
One of the most effective of these drugs is cyclo­
phosphamide, also known as Cytoxan (Mead Johnson Laboratories, 
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Evansville, Ind.). 
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Cytoxan is an alkylating agent and like other nitrogen 
mustards it reacts with many nucleophilic substances within 
the cell including a number of biologically active groups 
such as phosphate, amino, sUlfhydryl, hydroxyl, imidazo~e 
and carboxyl groups (Livingston and Carter, 1970). The 
first attempt to explain the mechanism of action of nitrogen 
mustard drugs proposed the formation of' an ethylenimine 
intermediate • 
This three member ring can either hydrolyze or alkylate one 
of the biologically active groups previously mentioned 
(Furst, 1963). This internal cyclization is necessary for 
the biological activity of all these drugs. 
In the case of Cytoxan, the drug cannot be ionized or 
activated until the ring is cleaved at the level of the 
phosphorous-nitrogen bond. Following this cleavage, internal 
cyclization to a three member ring probably occurs as in 
other nitrogen mustards. Thus, it is a metabolite of the 
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drug which gives the observed biological activity. This 
activation or cleavage is believed to occur in the microsomes 
of the liver rather than in the tumor cells themselves, even 
though it was originally believed that the high levels of 
phosphatase and phosphamidase in the tumor cells might acti­
vate Cytoxan in the tumor cells (Livingston and Carter, 1970). 
The active metabolite that produces the anti-tumor effect of 
the drug has not yet been isolated or identified (Bagley 
et al., 1973). 
Cytoxan has been shown to have great activity against 
Leukemia L1210. Schabel et all (1966) showed that a single 
maximum dose will reduce the number of L1210 cells in the 
peritoneum of BDF1 mice by 99.9%. Lane (1959) has shown 
that a single treatment with cyclophosphamide produces a high 
percentage of tumor-free survivors if the drug is administered 
early in the course of the disease. However, if the treatment 
was deferred until later in the disease, maximum effectiveness 
of the drug was achieved only when the drug was given at 
weekly intervals (Hoffman et al., 1969). 
With this evidence of the effectiveness of Cytoxan 
against L1210, research efforts were turned to dosage levels 
and treatment schedules in an attempt to determine the maxi­
mum efficiency of the drug. Venditti et ale (1959) observed 
that with a daily treatment schedule beginning early in the 
disease, none of the test animals exhibited total recovery 
from the leukemia. They also noted that using the daily 
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dose which yielded the greatest increase in survival time, 
Cytoxan toxicity for the host became extensive. When treat­
ment was begun later in the disease and the drug administered 
either as a single dose or every two days or every four days, 
the effectiveness of Cytoxan against L1210 increased as the 
interval between treatments was increased. 
Another drug which has shown a high degree of success 
against Leukemia L1210 is amethopterin or Methotrexate 
(Lederle Laboratories, Pearl River, N.Y.). Methotrexate 
is a folic acid antagonist which competitively inhibits 
dihydrofolate reductase and this results in a restriction of 
the amount of tetrahydrofolate available to the cell 
(Livingston and Carter, 1970). Methotrexate unites with 
dihydrofolate reductase, having an affinity 100,000 times 
greater than that of the normal substrate for the enzyme 
(Borsa and Whitmore, 1969). Since the supply of tetrahydro­
folic acid must be renewed to replace the amounts lost by 
oxidation, folic acid from the diet must be reduced to form 
tetrahydrofolic acid (Porter and Wiltshaw, 1962). Because 
Methotrexate competitively inhibits the action of dihydro­
folate reductase, no tetrahydrofolic acid can be formed and 
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DNA synthesis and replication are altered. The synthesis of 
DNA is much more sensitive to the action of Methotrexate than 
RNA. This probably is the result of a selective effect of 
Methotrexate on thyrnidylate synthesis since the efficiency of 
the drug can be altered by the addition of pre-formed 
thYmidine to the cell population in vitro (Borsa and Whitmore, 
1969). 
Aminopterin, another folic acid antagonist, was first 
used by Law et ale (1949) in the treatment of Leukemia 11210. 
They showed that the drug causes a significant increase in 
the survival time, a pronounced inhibition of the leukemic 
cell growth in the peritoneum, and an inhibition of the infil­
tration of the leukemic cells into the spleen, liver and 
axillary lymph nodes. Further work with aminopterin showed 
it to be severely toxic for the host, and Methotrexate, a 
methylated derivative of aminopterin, was found to reduce 
this problem. Friedkin and Goldin (1962) showed that treat­
ment with Methotrexate increased the life span of mice 
inoculated with L1210 leukemia cells. Hofer et ale (1969) 
confirmed this finding by labeling leukemic cells with 1251 _ 
iododeoxyuridine. They found that with daily treatments of 
Methotrexate (1 mg/kg) a similar fraction of the tumor cell 
population dies each day. 
Venditti and Goldin (1964) showed that it is possible 
with the use of sequential treatment to improve the therapeu­
tic response to advanced Leukemia L1210. This was achieved 
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by using a priming dose of cyclophosphamide, followed by daily 
or intermittent doseS of Methotrexate. Cyclophosphamide when 
used alone exerted its maximum degree of effectiveness on a 
weekly treatment schedule and the combination of daily 
Methotrexate plus weekly cyclophosphamide provided a marked 
therapeutic synergism. This advantage is attributable to a 
decrease or attenuation of the systemic leukemic cell papula­
tion from the initial treatment with cyclophosphamide fol­
lowed by SUbsequent growth retardation by Methotrexate. 
Straus et ale (1971) showed similar results when 
Methotrexate was used both as the priming dose and as the 
scheduled or intermittent dose. Here the priming dose effect 
was attributed to the possibility that the percentage of 
tumor cell kill of Methotrexate increases as the tumor cell 
population decreases. If this were so, the priming dose by 
lowering the tumor cell. number to a low level, would result 
in subsequen~ intermittent doses causing a greater percentage 
of kill for a given dose of the drug. 
straus et ale (1972) later compared the effect of the 
priming dose with respect to the drug used and the dosage. 
When cytoxan was us ed as the priming dos e, the survival time 
was increased over that which was obtained when Methotrexate 
was used at a comparable dose. By using a maximal single 
dose of Cytoxan (120 mg/kg) at day two followed by Methotrexate 
(4 mg/kg) every two days thereafter, it was possible to obtain 
the best chemotherapeu tic effect with the survival being 
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increased to about 27 days. This was about twice that 
achieved when either drug was used by itself and about four 
times longer than when untreated. 
At the same time that these drugs are exerting their 
anti-leukemic effect, they are also causing a depression of 
the host's defense mechanismso Cyclophosphamide, an alkyl­
ating agent, has several effectsl (1) It prevents the dif­
ferentiation of small lymphocytes into immunoblasts after 
antigenic stimulation. (2) It has a toxic effect on the 
immunoblasts that do develop. (3) It is an anti-mitotic 
drug. In contrast, Methotrexate appears to block the devel­
opment of a population of small lymphocytes, and also slows 
down the division of immunoblasts (Mihich, 1967). When 
treatment is concluded, the drug effect stops and both 
residual leukemic cells and sensitized lymphocytes begin to 
proliferate again (Mihich, 1969). The race between these 
two proliferating cell lines will determine the eventual 
outcome for the host. 
Immunotherapy 
Leucogenenol, a leucocytosis inducing factor, has been 
isolated from the mold, Penicillium gilmanii, as well as 
bovine and human liver (Rice, 1966; Rice and Shaikh, 1970). 
It has the properties of an enol and has the molecular 
formula, C1SH25NOS (Rice, 1971). 
Extensive chemical analysis of leucogenenol showed a 
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single spot on thin layer chromatography of silica gel when 
the slides were developed with methanol-benzene (1.19. v/v). 
ethanol-benzene (1119, v/v) , dioxane-benzene (1.9, v/v). The 
RF values in these systems were respectively 18. 28 and 66 
(Rice and Barrow, 1967). The ultraviolet absorption of 
leucogenenol isolated by thin layer chromatography showed no 
sharp maxima. Therefore, it was necessary to determine the 
relationship between optical density and concentration at 
several wavelengths. The relationships were found to be. 
optical density/concentration (mg/ml) = 1.030, 1.054 and 
1.285 at 264, 270 and 280 nm, respectively. Leucogenenol 
readily forms salts with sodium, potassium and calcium, and 
solutions of these salts in water retained their biological 
activity for over a year. An aqueous solution of leucogenenol 
itself, however, readily lost this activity at room tempera­
ture (Rice, 1971). When hydrolyzed it formed 1.2 dihydroxy­
3-methyl-5-oxycyclohexanecarboxylic acid, 3-hydroxY-3-hydroxy­
methyl-5-methylcyclohexane-1,2-dione, glycoaldehyde, amino­
acetaldehyde and ammonia. This evidence and spectroscopic 
data indicate that leucogenenol is 2-(1,2-dihydroxy-3-methyl­
5-oxocyclohexyl)-3,11-dihydroxy-11-(hydroxymethyl)-9-methyl­
1-oxa-5-azaspiro 5,5 undeca-2,4-dien-7-one. 
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Injection of leucogenenol. as lit~le as 1 mg/kg, 
elicits a leucocytosis without a febrile response (Rice, 
1968) and is not toxic when as much as 500 ug/g is injected 
into a mouse (Rice and Darden, 1968). Injection of 1 euco­
genenol, either intravenously or intraperitoneally, leads 
first to an increase in the concentration of neutrophils and 
later to an increase in the concentration of lymphocy-tes in 
the peripheral blood of rabbits and mice (Rice, Connolly. 
Aziz and McCurdy, 1971). This is accompanied by an increase 
in the number of myeloblasts in the bone marrow and lympho­
blasts in the spleen (Rice, Lepick and Darden. 1968). In 
mice (strain unspecified) which were injected with a large 
dose (200 ug/kg) of leucogenenol. a decrease in neutrophils 
to less than one-half of the normal and a corresponding 
q 
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greater than two-fold increase in lymphocytes was seen within 
4 hours after injection. This change remained relatively 
constant for 12 days (Rice, 196m. 
Studies of the biological activity of leucogenenol 
indicate that it stimulates DNA replication in the precursor 
cells and increases their rate of transformation (Rice, 
McCurdy and Aziz, 1971). Rice, Blum and Rene (1970) showed 
that the addition of leucogenenol to a tissue culture of 
lymphoblastoid cells increases the respiratory quotient as 
well as increasing the rate of replication, and concluded 
that leucogenenol's action in an animal is due to a direct 
effect of leucogenenol on the blood cells. Further evidence 
for this hypothesis came from studies with sublethally 
irradiated mice. Rice, Lepick and Hepner (1970) showed that 
these mice when injected with leucogenenol and SRBC exhibited 
a shorter latent period and a greater hemolysin titer than 
non-Ieucogenenol treated animals. These results indicate 
that leucogenenol increases the rate of transformation of 
precursor cells into cells capable of antibody synthesis. 
Rice and Ciavarra (1971) extended this idea by treating 
splenectomized rats with leucogenenol. Within 3 days after 
splenectomy, treated rats became capable of producing normal 
titers of hemolysin in response to injections of SRBC whereas 
untreated mice still showed reduced levels. 
Rice, Ciavarra and Borsos (1972) showed that injections 
of leucogenenol into splenectomized rats along with SRBC 
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resul ts in the forma tiotl of' normal titers of 198 hemolysin. 
This is the result of a marked increase in the concentration 
of antibody forming cells in the lymphatic tissue and the 
liver (Rice,. Das and Koo. 1972). Al though normal 198 titers 
were formed,. no increase i.n the peak ti ter was found. This 
is in contrast to the findings of Jacoby (1972) in which 
animals that were injected with several. doses of Ieucogenenol 
and SRBC showed increased hemol.ysin ti tars over that of non­
leucogenenol. treated contro1.s. From this evidence, it is 
concluded that leucogeneno~ acts by increasing the rate of 
trans forma tion of immunocompetent cells. possibly a type of 
lymphocyte, into antigen-reactive lymphocytes (Rice, Ciavarra 
and Borsos, 1972). 
SummarY 
It is the purpose of this stUdy to determine if leuco­
genenol used in conjunction with conventional chemotherapy 
can help maintain the immunocompetence of the host throughout 
the course of Leukemia L1210 disease. The number of leukemic 
cells will be kept at a low level through sequential chemo­
therapy, using Cytoxan and Methotrexate.. When chemotherapy 
is stopped, it has been stated that there will be a race 
between the residual leukemic cells and the remaining sens i­
tized lymphocytes.. By trea.ting the animals through the 
course of the disease with leucogenenol , it is postulated 
that the number of sensi tized lymphocytes will be increased 
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such that this race will be turned in the host's favor. 
METHODS AND ]\IIA TERIALS 
Leukemia L1210 
The Leukemia L1210 cell line, LE-29, used in these 
experiments was received from Mr. N. H. Greenberg of the 
National Cancer Institute. It was at generation B-10 when 
received. The leukemic cells were carried in DBA/2 mice by 
intraperitoneal injection of lXl05 viable cells. Ascites tumor 
cells were counted in a hemocytometer and their viability 
determined by the Trypan Blue exclusion method. The cells 
were then diluted in Hank's balanced salt solution to lxl06 
viable cells per milliliter. The suspension was kept in an 
ice bath until ready for use and each test animal then re­
ceived 0.1 ml (lxl05 ) viable leukemic cells. 
Mice used in this experiment were C3D2F /J males,1
approximately 25 grams in weight. They were obtained from 
The Jackson Laboratories, Bar Harbor, Maine. The DBA/2J 
male mice in which the tumor line was carried were also ob­
tained from this laboratory. All animals were kept in groups 
of 5 and 6 in plastic disposable cages with sterilized saw­
dust. Water and standard laboratory chow were given ad 
libitum. 
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Drugs 
Cytoxan (cyclophosphamide; Mead Johnson Laboratories. 
Evansville. Ind.) was dissolved in sterile non-pyrogenic 
0.85% NaCl and injected intraperitoneally at a dose of 120 mg 
per kilogram of body weight. Methotrexate (Nutritional Bio­
chemical Corporation, Cleveland. Ohio) was freshly prepared 
at each injection time. It was dissolved in sterile non­
pyrogenic 2% sodium bicarbonate and injected intraperitoneally 
at a dose of 4 mg per kilogram of body weight. 
Antigenic Stimulation 
The status of the humoral immune response was monitored 
by the injection of a 10% suspension of sterile SRBC. These 
cells were washed three times in sterile saline and then 
diluted to a 10% suspension with sterile saline. Each animal 
received 0.1 ml doses at days 0, 7 and 14. Serum for antibody 
titers was collected for each animal when sacrificed. The 
serum was separated from the whole blood after the cellular 
elements had clotted and were centrifuged out. The serum was 
decanted from the tUbe and frozen immediately. Both hemolysin 
and hemagglutination titers were done by standard microtiter 
techniques. For hemagglutination titers •• 025 ml of serum, 
.050 ml of veronal buffered saline and .025 ml of 2% SRBC were 
used. For hemolysin titers •• 025 ml of serum, .025 ml of 
veronal buffered saline, .025 ml of a le15 dilution of guinea 
pig complement and .025 ml of 2% SRBC were used. All titers 
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were read as the last dilution showing a positive result and 
reported as the Log2 • 
Leucogenenol 
Leucogenenol was isolated using the procedure of Rice 
(1966) with several minor modifications. Approximately 20 
grams of lyophilized bovine liver were extracted with 80 or 
90 ml of methanol in a Soxhlet apparatus. Equal volumes of 
liver from three different lots were used and were extracted 
for 24 hours. These extracts were pooled until approximately 
1000 grams of liver powder had been extracted. The pool was 
then evaporated at 40-50oC to a thick syrup in a flash evapor­
ator under 20-22 rom Hg pressure. Subsequent steps were 
similar to that of Rice (1966). Leucogenenol was dissolved 
in sterile non-pyrogenic water and used at a concentration of 
8 ug per animal in 0.2 mI. 
Experimental Procedure 
Cytoxan was given two days following L1210 leukemic 
cell inoCUlation and Methotrexate was given every two days 
beginning on the fourth day after infection until day sixteen 
when the last injection was given. Leucogenenol was given 
two days prior to infection as well as day J. 7. 14 and 21 
after infection. 
A total of 114 animals were used and they were divided 
into the following groups I 
Group I: Normals - 3 sub-groups of 6 animals. 
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Group II I Leukemia L1210 controls - 2 sub-groups of 
6 animals. 
Group 1111 Leukemia L1210 + Cytoxan - 3 sub-groups 
of 5 animals. 
Group IV I Leukemia L1210 + Methotrexate - 3 sub­
groups of 5 animals. 
Group V Leukemia L1210 + Leucogenenol - 3 sub­
groups of 6 animals. 
Group VI. Leukemia L1210 + Cytoxan + Methotrexate 
3 sUb-groups of 6 animals. 
Group VII. Leukemia L1210 + Cytoxan + Methotrexate + 
Leucogenenol - 3 sub-groups of 6 animals. 
The first sUb-group of each group was sacrificed on day 7; 
the second sUb-group was sacrificed on day 14 except for 
Groups II and V in which no animals were still living; the 
third sUb-group was kept for survival data. 
Blood samples at day 7 and day 14 were obtained by 
decapitation and blood collected for differential smears, 
hematocrits. total nucleated cell counts and ~ntibody studies. 
The nucleated cell counts were made with the Coulter Counter, 
Model B, in which 20x of blood was diluted in 10 ml of 
diluting fluid (Coulter Counter, Inc.; Hialeah, Florida). 
Differentials were stained with Wright's stain and 100 
cells were counted and classified. Multiple counts were made 
on questionable differentials and the average of these counts 
used. 
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Hematocrits were made using pre-calibrated Micro­
Hematocrit Tubes (Clay Adams No. 1025: Parsippany, N.J.). 
The tubes were then sealed and centrifuged for five minutes 
in an Adams' Micro-Hematocrit Centrifuge. The values were 
then read directly from the pre-calibrated scale. 
Upon termination, all animals were weighed and then 
the spleens and livers removed and weighed. Ratios of the 
spleen and liver weight to the total body weight were then 
determined. The relative enlargement of the inguinal and 
axillary lymph nodes was also observed at this time. 
Statistical analyses were carried out by using a t­
test for simple correlation (Chou, 1969). The p values were 
then determined from a standard t distribution table. The 
criteria for significance was p L .1. 
RESULTS 
In reporting the differential counts for the various 
animal groups in these experiments, the term lymphoid cell 
is used instead of lJ~phocyte to avoid confusion and contro­
versy. Thus, small, large and immature lymphocytes were all 
Classified in this one category. Although no significant 
change occurred in the number of monocytes and eosinophils, 
their results are shown in Table 1. 
Normal CDF1 control animals showed similar differ­
ential counts at each bleeding during the experiment with 
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Table 1. Average Differential Counts. 
% % % % 
Animal Group Day Lymphoid PMN Monocytes Eosinophils 
Group I 7 70.0 26.6 1.2 2.2 
Normal Control 
14 69·3 26·5 2.0 2.2 
Group II 7 28.2 69.6 1.8 0.4 
L1210 Control 
14 
----* 
Group III 7 81.4 18.0 0.6 0.0 
L1210 + Cytoxan 
14 23·0 75·3 1·7 0.0 
Group IV 7 75·8 21.6 1.8 0.8 
L1210 + lVlTX 
14 28·3 70.2 0·5 1.0 
Group V 7 34.2 65·0 0·5 0·3
L1210 + 
Leucogenenol 14 
----* 
Group VI 7 95·7 4·3 0.0 0.0 
L1210 + Cytoxan 
+ MTX 14 48·5 5°·1 0·7 0·7 
Group VII 7 96·3 3·7 0.0 0.0L1210 + Cytoxan 
+ lVITX 14 5900 39.6 0·7 0·7 
+ Leucogenenol 
~n*No animals were living • these groups at day 14. 
....
 
Figure 1. Average percent lymphoid cells from 
peripheral differential smears. No animals were living 
at day 14 in Groups II and V. 
Group I I Normal Controls 
Group II I L1210 Controls 
Group 1111 L1210 + Cytoxan 
Group IV L1210 + Methotrexate 
Group V L1210 + Leucogenenol 
Group VI I L1210 + Cytoxan + Methotrexate 
Group VIII L1210 + Cytoxan + Methotrexate 
+ Leucogenenol 
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lymphoid cell counts in the range of 65%-77% with an average 
of 70.0% and polymorphonuclear cells (PMN's) in the range of 
20%-)2% with an average of 26.6%. These counts were greatly 
changed in the L1210 controls. Mice in this group had 
lymphoid cell counts that ranged from 24%-)1% and PMN counts 
in the range of 66%-74%. When L1210 infected animals were 
treated with either drug, this reduction in the number of 
lymphoid cells was delayed. L1210 animals that were treated 
with Cytoxan exhibited 81.4% lymphoid cells at day 7 com­
pared to 69.6% for L1210 controls (p L .01), while animals 
treated with only Methotrexate showed 75.8% lymphoid cells 
(p L .1). However, at the fourteenth day after infection, 
the counts for both groups were reversed. L1210 infected 
animals treated with Cytoxan showed 23.0% lymphoid cells and 
those treated with Methotrexate showed 28.)% lymphoid cells. 
These values approached the levels that the untreated con­
trols showed at day 7. When these drugs were combined in 
the treatment of infected animals, there was a marked increase 
in the percentage of lymphoid cells at day 7 as compared to 
groups treated with either drug alone (p L .001). The per­
centage of lymphoid cells dropped from 95.7% at day 7 to 48.5% 
at day 14 and this value was again significantly higher than 
either group which received only one drug (p L .001). 
When L1210 animals were treated with leucogenenol. the 
percentage of lymphoid cells was higher than that of the 
L1210 controlS (p ~ .05), showing 34.2% lymphoid cells at 
24 
day 7· If leucogenenol treatment was given in conjunction 
wi th combined chemotherapy. there was no significant change 
(p=NS) in the differential counts at day 7 over that of 
animals receiving only drug therapy. At day 14. however. the 
leucogenenol treated animals showed 59.0% lymphoid cells 
while non-Ieucogenenol treated animals showed 48.5% lymphoid 
cells (p L .1). 
The hematocrit values of all animal groups are shown 
in Table 2 and Figure 2. Uninfected CDF control animals1 
showed little difference in their hematocrits throughout the 
experiment, showing values of' 49.0 and 49.2 at days 7 and 14 
respectively. while L1210 in:fected animals showed a lower 
hematocrit of 30.0 (p ~ .001) at day 7. Drug treated animals 
showed similar hematocrits to that of L1210 controls at day 7. 
but at day 14, Cytoxan treated animals showed a lowered 
hematocrit of 28.2. When chemotherapy was combined. the 
hematocrit showed little change at day 7 but was reduced to 
16.7 at day 14; this was the lowest hematocrit value recorded 
for any group. L1210 infected animals that were injected 
with leucogenenol showed a hematocrit of 27.5 at day 7 which 
was significantly lower than L1210 controls at the same time 
(p L .05), and when leucogenenol was given with combined 
chemotherapy, the hematocrit value was higher than in animals 
receiving only combined chemotherapy at day 7. However, this 
was not a significant difference. At day 14, the animals 
receiving leucogenenol. with chemotherapy showed a hema tocri t 
25 
Table 20 Average Hematocrit Values. 
Animal Group 
Group I
Normal Control 
Group II 
L1210 Control 
Group III 
L1210 + Cytoxan 
Group IV
L1210 + MTX 
Group V 
L1210 + Leucogenenol 
Group VI 
L1210 + Cytoxan 
+ MTX 
Group VII 
L1210 + Cytoxan 
+ lVITX 
+ Leucogenenol 
Day 
7 
14 
7 
14 
7 
14 
7 
14 
7 
14 
7 
14 
7 
14 
Hematocrit (Average) 
49·0 
49.2 
30.0 
----*
 
30.0 
35·7 
29·4 
28.2 
27·5 
----*
 
27·1 
16.7 
28.8 
2J·5 
*No animals were living in these groups at day 14. 
Figure 2. Average hematocrit values. No 
animals were living at day 14 in Groups II and V. 
Group I I Normal Controls 
Group II: L1210 Controls 
Gro~p IlIa L1210 + Cytoxan
Group IV: L1210 + Methotrexate 
Group V a L1210 + Leucogenenol
Group VI: L1210 + Cytoxan + Methotrexate 
Group VII: L1210 + Cytoxan + Methotrexate 
+ Leucogenenol 
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of 23·5 versus 16.7 for groups receiving only combined chemo­
therapy (p L .05). 
The average nucleated cell counts for all animal 
groups can be seen in Table 3 and Figure 3. While uninfected 
control animals showed similar counts at days 7 and 14 of 
6.06 and 6.16 x 103 cells/cu mm respectively, the L1210 con­
trols showed an elevated count of 15.54 x 103 cells/cu mm at 
day 70 Drug treated groups usually showed decreased nucleated 
cell counts and the group given combined chemotherapy had the 
lowest value of 1093 x 103 cells/cu mm at day 7. The group 
that received only Methotrexate was an exception and instead 
of having a leukopenia had relatively normal counts of 6.71 x 
103 cells/cu mm at day 7 and 5.51 x 103 cells/cu rom at day 14. 
In contrast, the remaining groups showed elevated counts at 
day 14. Those animals that received only Cytoxan showed 
91.18 x 103 cells/eu mm while those receiving both drugs in 
combination showed 6.8 x 103 cells/eu mm. 
When 11210 infected animals were injected with leuco­
genenol, the total counts were significantly higher than that 
of the L1210 controls (p> .1) at day 7. When leucogenenol 
was administered along with chemotherapy, the nucleated cell 
count reached its lowest level at day 7 of 1.11 x 103 cells/ 
cu mm. This was significantlY lower than for animals re­
ceiving only combined chemotherapy (p L. 001 ) • However, by 
day 14, the count for leucogenenol and drug treated animals 
had increased to 20009 x 103 cells/cu mm, while those animals 
29 
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Table 3· Average Peripheral Nucleated Cell Counts X 103 
Cells7cu rom. 
Animal Group Day 7 Day 14 
Group I 
Normal Controls 
Group II 
L1210 Controls 
Group III 
L1210 + Cytoxan 
Group IV 
11210 + MTX 
Group V 
L1210 + Leucogenenol 
Group VI 
L1210 + Cytoxan + MTX 
Group VII 
L1210 + Cytoxan + MTX 
+ Leucogenenol 
6.06 
15.54 ----* 
2 •.57 
20.86 ----* 
6.80 
20,,09 
*No animals were living in these groups at day 14. 
nt 
Figure J~ Average peripheral total nucleated 
cell count x 10J cells/ell mm. No animals were living 
at day 14 in Groups II and V. 
Group I I Normal Controls
 
Group II I L12l0 Controls
 
r..J':'f'lll'Q.. ITI.J 1..12t11 + C'ltoxan 
Group IV, L1210 + Methotrexate 
Group V , L12l0 + Leueogenenol 
Group VI I L1210 + Cytoxan + Methotrexate 
Group VII, L1210 + Cytoxan + Methotrexate 
+ Leueogenenol 
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receiving combined chemotherapy showed only 6.80 x 103 cells! 
cu mm (p L .001). 
The average survival times in days can be Seen in 
Table 4 and Figure 4. 11210 controls showed an average sur­
vival time of 8.3 days. This was not significantly different 
from an average of 8.0 days for L1210 animals treated with 
leucogenenol. All remaining groups showed increased survival 
times. Those that received Cytoxan lived an average of 13.0 
days while those that received Methotrexate survived an 
average of 15.0 days. If these drugs were combined, the sur­
vival time was increased to 26.0 days compared to 23.8 days 
when leucogenenol was given in conjunction with combined 
chemotherapy (p > .1). 
The ratio of spleen and liver weight to total body 
weight can be seen in Table 5 and Figure 5. These ratios 
were calculated after the animals died or in the case of the 
normals when sacrificed. 11210 controls showed a ratio 
greater than that of the uninfected controls, .077 compared 
to .060 (p=NS). When infected animals were treated with 
leucogenenol, this ratio was increased to .089 (p=NS). 
Following the administration of combined chemotherapy, the 
ratio was further increased. Animals that received combined 
chemotherapy showed the highest ratio, .161, while those 
that received leucogenenol along with combined chemotherapy 
Showed a slightly decreased ratio. It should be noted that 
the ratio for treated groups increased as the survival time 
'_------------------1
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Table 4. Average Survival Times in Days. 
Animal Group Survival Time Range 
(Average in Days) 
Group I 
Normal Control 
Group II 
L1210 Controls 
Group III 
L1210 + Cytoxan 
Group IV 
L1210 + MTX 
Group V 
L1210 + Leucogenenol 
Group VI 
L1210 + Cytoxan + MTX 
Group VII 
L1210 + Cytoxan + MTX 
+ Leucogenenol 
----* 
13·0 
1500 
8.0 
26.0 
23·8 
-----*
 
8- 9 
12-14 
14-16 
7- 9 
22-33 
20-26 
*No deaths occurred in the normal controls. 
:F'ig'J.re 4. Average survival times in days. 
Normals not included. 
Group II ~ L1210 Controls 
Group III~ L1210 + Cytoxan 
Group IV 1 L1l10,. z.:ethotrexate 
Q.rQ~Jt ¥ ~ :L:t.at.Q -+ :L,~iJJ;;Q~~11~nQl 
Group VI: L1210 + Cytoxan + Methotrexate 
Group VII. L1210 + Cytoxan + Methotrexate 
+ Leucogenenol 
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Table 5. Average ratio of the spleen and liver weight to the 
total body weight. 
Animal Group Liver + Spleen Wt./Total Body Wt. Range 
(Average) 
Group I 
Normal Control 
.060 .056-.061 
Group II 
L1210 Control 
.077 .064-0091 
Group III 
L1210 + Cytoxan 
.116 (3)* .106-.128 
Group IV 
L1210 + MTX 
.117 (4) .100-.136 
Group V 
11210 + Leucogenenol 
.089 .080-.110 
Group VI 
11210 -+- Cytoxan 
-+­ MTX 
.161 
Group VII 
11210 + Cytoxan 
+ Leucogenenol 
-+­ MTX 
.153 .137-0184 
*Six animals were used per group unless specified, in which 
case, the number in parenthesis represents the number of 
animals used to calcUlate the average. 
Figure 5. Average weight ratio of the liver 
and spleen compared to the total body weight. 
Group I I Normal Controls 
Group II r L1210 Controls 
Group Ills L1210 + Cytoxan 
Group Iv I 11'21'0 -+ W£E/tllotr~Rt~ 
Group V I L1210 + Leucogenenol 
Group VI s L1210 + Cytoxan + Methotrexate 
Group VIII L1210 + Cytoxan + Methotrexate 
+ Leucogenenol 
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increased. 
Antibody studies are shown in Table 6 and Figures 6 
and 7. L1210 controls showed no significant difference in 
either hemagglutination (HA) or hemolysin titers from that of 
normal controls at day 7 (p=NS). Infected animals which were 
injected with leucogenenol showed slightly decreased titers 
compared to L1210 conbrols but this was not a significant 
difference. All animals that received drug treatment showed 
significantly reduced titers. Those animals receiving Cytoxan 
showed HA titers of 1.00 and 2.67 at days 7 and 14 respective-
lye These animals exhibited the same values for hemolysin 
titers at days 7 and 14. Animals receiving Methotrexate 
showed reduced HA titers of 4.60 and 2.50 and hemolysin titers 
of 4.60 and 3.50 at days 7 and 14 respectively. In animals 
with combined therapy, HA titers of 1.67 and 1.83 and ii 
:1 
1~ 
hemolysin titers of 1.17 and 2.17 were found at days 7 and I! 1 
14 respectively. If leucogenenol was administered along with 
combined chemotherapy, there was no significant difference in 
either HA or hemolysin titers as compared to animals receiving 
only combined chemotherapy. However, by day 14, both titers 
were increased over that of groups receiving only chemotherapy. 
They showed an average HA titer of 3.17 and an average hemo­
lysin titer of 3.00 compared to 1.83 and 2.17 respectively 
;v;ng combined chemotherapy (p L .05 for HAfor animals rece.. ..
 
and p=NS for hemolysin).
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Table 6. Average hemagglutination and complement-fixation
titers to SRBC at day 7 and day 14 (expressed as 
Log2 • 
Hemagglutination Complement-fixation
Animal Group Day Titers Titers (Average) (Average) 
Group I 
Normal Controls 
7 7·33 6.67 
14 7.67 7·50 
Group II 
11210 Con:brols 
7 
14 
7020 
----* 
6.80 
Group III 
L1210 + Cytoxan 
7 
14 
1.00 
2.67 (3 )** 
1.00 
2.67 (3)** 
Group IV 
L1210 + MTX 
7 
14 
4.60 
2 •.50 (4) 
4.60 
3·50 (4) 
Group V 
L1210 
+ Leucogenenol 
7 
14 
6.67 
----* 
6 •.50 
----* 
Group VI 
L1210 + Cytoxan 
+ MTX 
7 
14 
1.67 
1.83 
1.17 
2.17 
Group VII 7 1.00 1.00 
L1210 + 
+ MTX 
Cytoxan 
14 3·17 3·00 
+ Leucogenenol 
*No animals were living in these groups at d~y.14.. . 
**Six animals were used per group unless spec~f~ed. ~n wh~ch 
case. the number in parenthesis represents the number of 
animals used to calculate the average. 
•
 
Figure 6. 
expressed as 1og2 • Groups	 II and V. 
Group I I 
Group II I 
Group 1111 
Grou'P IV , 
Group V : 
Group VI I 
Group VII. 
Average SRBC hemagglutination titers 
No animals were living at day 14 in 
Normal Controls
 
L1210 Controls
 
L1210 + Cytoxan
 
11210 + Methotrexate
 
L1210 + Leucogenenol
 
L1210 + Cytoxan + Methotrexate
 
L1210 + Cytoxan + Methotrexate
 
+ Leucogenenol 
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Figure 7- Average SRBC hemolysin titers expressed 
as Log2 8 No animals were living at day 14 in Groups II and V. 
Group I Normal Controls 
Group II a L1210 Controls 
Group Ills L1210 + Cytoxan 
..
.. L1210 +- ~~e~g=ener~el 
G:,raup n t Ll..2-10 + C,y-t~xan + lIetbtrtrezata 
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DISCUSSION
 
The isolation and the biological activity of the lot 
of leucogenenol used in this experiment was previously re­
ported by Jacoby (1972). He indicated that leucogenenol 
might be more effective in the treatment of leukemias if it 
were given after an initial course of anti-tumor drugs and 
in a system in which a virus is not known to be actively 
proliferating within the precursor cell stimulated by leuco­
genenol. The findings of this study do not support this 
hypothesis. Although there was a significant beneficial 
change in some of the parameters of the disease when leuco= 
genenol was administered after chemotherapy, a minimal 
detrimental effect was observed in the survival times of the 
animals. 
Leucogenenol treated animals showed increased total 
nucleated cell counts, hematocrits and percent lymphoid cells 
in the peripheral blood compared to non-Ieucogenenol treated 
animals by day 14. The total nucleated cell count was the 
only parameter of the disease which indicated an enhancement 
of the leukemia, While both the increased hematocrit and the 
increased percentage of lymphoid cells would seem to be bene­
ficial to the host. However, even though leucogenenol was 
sUccessful in bringing about beneficial changes in parameters 
of the disease, it showed little effect on the survival times 
of the animal groups involved. Little can be said of the 
£ 
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spleen and liver weights since the only correlation that can 
be drawn is that the longer the animal survives after being 
infected with Leukemia L1210. the greater will be the sp1een 
and liver to total body weight ratios. Thus, leucogenenol. 
while influencing in a beneficial fashion some parameters of 
the disease, had only a minimal enhancing effect on the sur­
vival times of the mice. 
Rice. Das and Koo (1972) have reported that splenectom­
ized rats injected with leucogenenol showed normal antibody 
titers, but no increase in the peak titer. The results o:f 
this experiment confirm their finding. L1210 infected 
animals did not show a significant suppression of the immune 
response and when treated with leucogeneno1 showed little 
change in either HA or hemolysin titers. These titers in 
either case never went above the level of normal animals. 
This seems to suggest that there is a cellular control or 
feedback mechanism which controls the amount of antibody 
produced in response to an antigenic stimulation. The lack 
of immunosuppression in 11210 infected animals can best be 
explained by the time of antigenic stimulation in relation to 
the state of the disease. As previously stated, the humoral 
immunological response varies over the course of the disease. 
Bonrnasser, et ale (1971) showed that with immunizations early 
in the course of the disease, there is no decrease in the 
number of anti-SRBC plaque forming cells per spleen. Thus, by 
early antigenic stimulation the cells have already been 
47 
committed and are not affected by the leukemia throughout the 
course of the disease. The administration of leucogenenol 
did not raise either the HA or hemolysin titer past its peak 
value. The near normal humoral antibody levels obtained in 
these experiments was obviously not effective in controlling 
the number of proliferating L1210 leUkemic cells. Fass and 
Fefer (1972) have suggested that the presence of immune 
lymphocytes as the sole basis for anti-tumor therapy is 
ineffective after the tumor becomes detectable. This is 
believed to be due to the unfavorable ratio of immune cells 
to tumor cells. Hence, the effect of leucogenenol was not 
great enough to change this unfavorable ratio, and the num­
ber of tumor cells was too great for the host to immunological­
ly destroy them. 
The depression of the immune response during combined 
chemotherapy as previously stated (Mihich, 1967) was con­
firmed by the greatly reduced HA and hemolysin titers found 
in these experiments. Although by day 14, the humoral titers 
were increased by leucogenenol, they were never close to 
normal levels. These reduced levels of humoral antibody, 
even after the number of leukemic cells had been reduced, 
were not able to affect the disease to a~ great extent. 
This can best be explained in light of Mihich's (1969) theory 
Which has previously been mentioned. When treatment was con­
clUded, the race between the residual leukemic cells and the 
sensitized lymphocytes begins. In this case, leucogenenol 
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was not able to raise the antibody levels to a high enough 
level to overcome the residual leukemic cells and therefore 
the rapidly growing residual leUkemic cells proliferated 
faster than the remaining immune lymphocytes following dis­
continuance of chemotherapy. 
Since L1210 cells have an associated mammary tumor 
virus (MTV) or related antigen (ML), it would be expected 
that leucogenenol through its action would stimulate an en­
hanced specific immune response to these new antigens. This 
immunological response of the host would lead to the death 
of the leukemic cell population. The results of this experi­
ment, however, indicate that the immune response even though 
stimulated by leucogenenol was still not strong enough to 
overcome the leUkemic cell population. 
While humoral antibody levels were increased by treat­
ment with leucogenenol, recent evidence has shown that this 
may not necessarily be beneficial to the host. Hellstrom and 
Hellstrom (1970) showed that humoral antibodies may cause a 
phenomenon known as immunological enhancement of a tumor. It 
is now known that one of the main purposes of T-Iymphocytes 
is the inhibition or destruction of tumor cells (Hellstrom 
et al., 1968). However, the presence of humoral antibodies 
directed to the same tumor antigens as the sensitized lympho­
cytes can combine with the antigenic determinates on the tumor 
cells and block the cytotoxic action of the T-Iymphocytes. 
If these sites are blocked by the high titers of humoral 
2 
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antibody, then the tumor cell population will continue to 
proliferate since the cells are not accessible to the cyto­
toxic action of the sensitized lymphocytes (Sinkovics, Reeves 
and Cabiness, 1972). 
Hence, since leucogenenol stimulated increased levels 
of humoral antibodies while drug treatment was given, these 
antibodies may in fact have been coating the tumor cell anti­
gens. This would have the effect of rendering them inacces­
sible to the cytotoxic action of any sensitized lymphocyte 
produced. If this blocking effect did occur it had a minimal 
but significant effect on the survival times of the animals 
tested. 
This stUdy leaves many questions to be answered. All 
studies of leucogenenol at this point indicate that it stimu­
lates the humoral immune response in immunosuppressed animals 
(Rice, Lepick and Darden, 1968; Rice and Ciavarra, 1971; 
Jacoby, 1972). This would suggest that leucogenenol is 
definitely stimulating B cells. Is leucogenenol's action 
specific for the B cells or does it affect both Band T cell 
lines? This is especially important for two reasons. 
Hellstrom and Hellstrom (1970) showed that humoral antibodies 
can cause immunological enhancement of a tumor while T cells 
are largely responsible for the cytotoxic effect on tumor 
cells. It is also important from the standpoint of the cell 
line affected by the leukemia. A recent study by Thomas 
(1972) showed that the L1210 cell is derived from the B cell 
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precursor while studies are still underway to determine which 
cell line is affected by various other experimental and human 
leukemias- Does leucogenenol playa role in oncogenesis and 
is it present in increased levels in oncogenic tissue where 
cells are rapidly dividing? If this is the case, would an 
antibody directed to leucogenenol be effective in slowing 
down the tumor growth? Answers to these questions may pro­
vide a better understanding of the cellular control of 
abnormal tumor cell division. 
The purpose of this experiment was to determine if 
leucogenenol in conjunction with conventional chemotherapy 
can enhance the survival of L1210 infected animals. The 
initial findings indicated that some of the parameters of the 
leukemia were reduced. An increased hematocrit, an increase 
in the percent of lymphoid cells in the peripheral blood and 
increased antibody titers indicated that the infected animals 
might be successfully fighting off the leukemia. However, 
these changes in the parameters of the disease did not signi­
ficantly increase the final survival time of the test groups. 
It was therefore concluded that leucogenenol was able to in­
crease the humoral antibody response but not the number of 
sensitized lymphocytes such that the residual leukemic cells 
could be destroyed immunologically. Hence, even in combination 
51 
with chemotherapy, leucogenenol's action could not turn the 
race between the residual leukemic cells and sensitized 
lymphocytes in favor of the host under the conditions of 
these experiments­
52 
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